KBC Group’s Viking Therapeutics VKTX Stock Holding History

KBC Group’s Portfolio VKTX Stock Details VKTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$129K	Hold	3,960	–	–	﹤0.01%	1248
2026 Q2	$154K	Hold	3,960	–	–	﹤0.01%	1161
2026 Q1	$129K	Buy	3,960 +1,030	+35%	+$33.1K	﹤0.01%	1175
2025 Q4	$103K	Hold	2,930	–	–	﹤0.01%	1256
2025 Q3	$77K	Hold	2,930	–	–	﹤0.01%	1432
2025 Q2	$78K	Sell	2,930 -1,354	-32%	-$35.6K	﹤0.01%	1370
2025 Q1	$103K	Buy	4,284 +30	+0.7%	+$948	﹤0.01%	1469
2024 Q4	$171K	Buy	4,254 +1,257	+42%	+$71.7K	﹤0.01%	1219
2024 Q3	$190K	Buy	2,997 +473	+19%	+$27.8K	﹤0.01%	958
2024 Q2	$134K	Buy	2,524 +736	+41%	+$48.2K	﹤0.01%	1026
2024 Q1	$147K	Buy	+1,788	New	+$79.6K	﹤0.01%	949
2023 Q4	–	Sell	-1,445	Closed	-$16K	–	1909
2023 Q3	$16K	Buy	+1,445	New	+$20.7K	﹤0.01%	1905

Other funds holding VKTX

Fidelity Investments Boston, Massachusetts $2.32T AUM 44.66% 1-Year Est. Return

BlackRock New York $6.79T AUM 37.06% 1-Year Est. Return

State Street Boston, Massachusetts $3.44T AUM 36.12% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.76T AUM

Vanguard Portfolio Management Malvern, Pennsylvania $2.21T AUM

Morgan Stanley New York $1.96T AUM 27.49% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return

American Century Companies Kansas City, Missouri $229B AUM 33.35% 1-Year Est. Return

UBS Group Zurich, Switzerland $765B AUM 28.39% 1-Year Est. Return

BNP Paribas Financial Markets Paris, France $294B AUM 47.59% 1-Year Est. Return

KBC Group's VKTX Position: Q3 2026 in Review

KBC Group held its Viking Therapeutics (VKTX) position steady in Q3 2026 at 3,960 shares worth $129K. The position accounts for ﹤0.01% of the portfolio, ranked #1248.

KBC Group first reported a position in VKTX in Q3 2023 and has held it in 12 quarters since. The position peaked at $190K in Q3 2024. 322 funds tracked by Wall St. Rank hold VKTX as of Q3 2026.

KBC Group held 3,960 shares of Viking Therapeutics worth $129K as of Q3 2026.
KBC Group left its Viking Therapeutics share count unchanged in Q3 2026.
Viking Therapeutics made up ﹤0.01% of KBC Group's portfolio in Q3 2026, its #1248 holding.
KBC Group first reported a position in Viking Therapeutics in Q3 2023 and has held it in 12 quarters since.
KBC Group's Viking Therapeutics position peaked at $190K in Q3 2024.
322 funds tracked by Wall St. Rank held Viking Therapeutics as of Q3 2026.

Based on KBC Group's 13F filing for Q3 2026, filed 22 Oct 2026.